Month: August 2025

Energi to acquire 51% of Tembo with VivoPower continuing to hold a significant shareholding in Tembo post-SPAC merger Energi is supportive of Tembo’s business combination with Cactus Acquisition Corp 1 Limited (“SPAC”) at an equity valuation of $838 million Tembo can now resume finalizing and filing the F-4 SPAC Registration Statement LONDON, Aug. 18, 2025 (GLOBE NEWSWIRE) — VivoPower International PLC (NASDAQ: VVPR) (“VivoPower” or the “Company”) today announced it has reached agreement with Energi Holdings Limited (“Energi”) whereby Energi will proceed to secure a 51% shareholding in Tembo e-LV B.V. (“Tembo”) via a strategic PIPE investment at the previously advised total enterprise valuation of $200 million. This confirmation will now enable the resumption of Tembo’s proposed business combination with the special purpose acquisition...

Move Strengthens Strategic Ties with the Association for Uncrewed Vehicle Systems International and Advances Trusted Operator Initiatives MONROE TOWNSHIP, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative, low-carbon offshore power, data, and service solutions, today announced the opening of a new office at the Association for Uncrewed Vehicle Systems International (AUVSI) headquarters in Washington, D.C. This strategic move marks a significant milestone in the Company’s expansion efforts and underscores its commitment to advancing uncrewed systems operations and policy engagement at the national level. The new office, located in the heart of the U.S. capital, positions OPT alongside the world’s largest nonprofit organization dedicated to...

ENX-CL-05-001 Trial: 3-months topline data –   In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. –   Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ –   Webinar today at...

VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company” or “Imperial”) (TSX:III) announces that all outstanding Senior Unsecured Convertible Debentures (the “Debentures”) due August 30, 2027 will be converted into common shares of the Company (“Debenture Shares”), with 100% of the holders of the Debentures (the “Holders”) electing to exercise their conversion rights prior to the conversion notice deadline (the “Conversion”). As a result, no cash redemption will be made on August 18, 2025 (the “Redemption Date”). The 14,687,500 Debenture Shares issuable upon conversion will be delivered to the Holders on the Redemption Date in lieu of the redemption price. As previously announced in the News Release dated July 14, 2025, the Company intended to redeem at par on the Redemption Date...

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the podium at the SNO/ASCO CNS Metastases Conference in Baltimore, MD. The data demonstrated treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal. The...

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced a long-term strategic partnership with Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in advanced cardiovascular imaging solutions. The collaboration reflects Circle CVI’s commitment to leveraging trusted, high-quality data to drive innovation in cardiac diagnostics, treatment planning, and AI model development with data being delivered in the next 30 days. Circle CVI selected OneMedNet’s iRWD™ platform to access diverse and regulatory-grade imaging, ECG, and other cardiovascular datasets that align with the stringent requirements of healthcare AI innovation. By partnering with OneMedNet, Circle CVI gains secure, de-identified access to...

TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”) (TSX: “AP.UN”) today provided an update with respect to pending completion of the final two ground-up developments in its development pipeline: M4 of Main Alley Campus, 108 East Fifth Avenue in Vancouver; and KING Toronto, 489-539 King Street West in Toronto. “Completing the large, multi-city development pipeline we initiated in 2012 has materially enhanced our ability to serve knowledge-based organizations,” said Michael Emory, Founder and Executive Chair. “We now have a much broader base of high-quality office and retail tenants, an expanded range of workspace options (Allied Heritage, Allied Modern and Allied Flex) and greater concentration in stronger and larger mixed-use, amenity-rich urban neighbourhoods.” M4...